The scientific journal Cancer published an original study called, “Early discontinuation of tamoxifen: A Lesson for oncologists.” Although the optimal length of tamoxifen therapy for preventing recurrence of breast cancer in patients is 5 years, this study found that more than one fifth of women patients stopped therapy. By the end of 3.5 yaers, more than one third of patients have stopped tamoxifen therapy. This was a study of over 2800 patients who received tamoxifen therapy between 2001 and 2004. This is a high rate of patient non-adherence (also called non-compliance or non-persistence) and raises a concern of sticking to a prevention regimen using an oral anticancer agents. Source: Cancer.
Latest Tips RSS
-
TargetingTumors.com
-
TargetingTumors.com
Today’s Wall Street Journal is reporting via the Associated Press that a panel of experts have asked the FDA to add a warning to the label for breast cancer drug tamoxifen because some women are genetically disposed to metabolize (process) the drug slower than other women. The processed form of tamoxifen - endoxifen - is the form that stops hormone dependent cell growth, which then stops or slows cancer growth. (More …)